Patents by Inventor Christoph Schumacher

Christoph Schumacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11135192
    Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Christoph Schumacher, Thomas Holbro
  • Publication number: 20210213820
    Abstract: A retaining system which may be used for locking an energy store, in particular for an electrically operable two-wheeled vehicle. The retaining system is designed such that it does not transfer any forces from the energy store to the retaining system in the locked or latched position.
    Type: Application
    Filed: July 11, 2019
    Publication date: July 15, 2021
    Inventors: Christoph Schumacher, Dennis Mehlo, Haris Alisic, Thilo Koeder, Volker Jabs, Lisa Bayer
  • Publication number: 20210169861
    Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.
    Type: Application
    Filed: May 2, 2019
    Publication date: June 10, 2021
    Inventors: Ronald Edward STEELE, Christoph SCHUMACHER
  • Patent number: 11024917
    Abstract: A retaining element provided for two-stage fastening to an accumulator or which is part of an accumulator, safeguards against removal from a retaining device. The retaining device is oriented toward the retaining element and is fastened in an interior of tubes of a bicycle frame of an electrically driven bicycle.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 1, 2021
    Assignee: Robert Bosch GmbH
    Inventors: Christian Trif, Christoph Schumacher, Frank Hummel, Martin Tenzer, Volker Jabs
  • Publication number: 20210024519
    Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.
    Type: Application
    Filed: August 12, 2020
    Publication date: January 28, 2021
    Inventors: Christoph SCHUMACHER, Walter FUHRER, Ronald Edward STEELE
  • Patent number: 10822332
    Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 3, 2020
    Assignee: DAMIAN PHARMA AG
    Inventors: Christoph Schumacher, Walter Fuhrer, Ronald Edward Steele
  • Patent number: 10549021
    Abstract: A pump having at least a fluid pump chamber (11) and a first driver chamber (12) separated from the fluid pump chamber (11) by an elastic wall (13, 13-1, 13-2) is described with the first driver chamber (12) expanding after a chemical reaction between fuel and oxidant and driving through deformation of the elastic wall fluid out of the fluid pump chamber (11), with the main parts of the pump being made of an elastic material to be used for example as a body implant.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: February 4, 2020
    Assignee: ETH Zurich
    Inventors: Wendelin Jan Stark, Christoph Schumacher, Roland Fuhrer, Michael Loepfe
  • Publication number: 20190292180
    Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 26, 2019
    Applicant: DAMIAN PHARMA AG
    Inventors: Christoph SCHUMACHER, Walter FUHRER, Ronald Edward STEELE
  • Publication number: 20190165347
    Abstract: A retaining element provided for two-stage fastening to an accumulator or which is part of an accumulator, safeguards against removal from a retaining device. The retaining device is oriented toward the retaining element and is fastened in an interior of tubes of a bicycle frame of an electrically driven bicycle.
    Type: Application
    Filed: May 12, 2017
    Publication date: May 30, 2019
    Inventors: Christian Trif, Christoph Schumacher, Frank Hummel, Martin Tenzer, Volker Jabs
  • Patent number: 10248581
    Abstract: Methods, systems, and machine readable medium for multi-thread safe system level modeling simulation (SLMS) of a target system on a host system. An example of a SLMS is a SYSTEMC simulation. During the SLMS, SLMS processes are executed in parallel via a plurality of threads. SLMS processes represent functional behaviors of components within the target system, such as functional behaviors of processor cores. Deferred execution may be used to defer execution of operations of SLMS processes that access a shared resource. Multi-thread safe direct memory interface (DMI) access may be used by a SLMS process to access a region of the memory in a multi-thread safe manner. Access to regions of the memory may also be guarded if they are at risk of being in a transient state when being accessed by more than one SLMS process.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 2, 2019
    Assignee: Synopsys, Inc.
    Inventors: Jan M. J. Janssen, Thorsten H. Grötker, Christoph Schumacher, Rainer Leupers
  • Publication number: 20180200218
    Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.
    Type: Application
    Filed: March 6, 2018
    Publication date: July 19, 2018
    Inventors: Christoph Schumacher, Thomas Holbro
  • Patent number: 9937143
    Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 10, 2018
    Assignee: Novartis AG
    Inventors: Christoph Schumacher, Thomas Holbro
  • Publication number: 20180032448
    Abstract: Methods, systems, and machine readable medium for multi-thread safe system level modeling simulation (SLMS) of a target system on a host system. An example of a SLMS is a SYSTEMC simulation. During the SLMS, SLMS processes are executed in parallel via a plurality of threads. SLMS processes represent functional behaviors of components within the target system, such as functional behaviors of processor cores. Deferred execution may be used to defer execution of operations of SLMS processes that access a shared resource. Multi-thread safe direct memory interface (DMI) access may be used by a SLMS process to access a region of the memory in a multi-thread safe manner. Access to regions of the memory may also be guarded if they are at risk of being in a transient state when being accessed by more than one SLMS process.
    Type: Application
    Filed: October 10, 2017
    Publication date: February 1, 2018
    Inventors: Jan M.J. Janssen, Thorsten H. Grötker, Christoph Schumacher, Rainer Leupers
  • Patent number: 9817771
    Abstract: Methods, systems, and machine readable medium for multi-thread safe system level modeling simulation (SLMS) of a target system on a host system. An example of a SLMS is a SYSTEMC simulation. During the SLMS, SLMS processes are executed in parallel via a plurality of threads. SLMS processes represent functional behaviors of components within the target system, such as functional behaviors of processor cores. Deferred execution may be used to defer execution of operations of SLMS processes that access a shared resource. Multi-thread safe direct memory interface (DMI) access may be used by a SLMS process to access a region of the memory in a multi-thread safe manner. Access to regions of the memory may also be guarded if they are at risk of being in a transient state when being accessed by more than one SLMS process.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: November 14, 2017
    Assignee: Synopsys, Inc.
    Inventors: Jan M. J. Janssen, Thorsten H. Grötker, Christoph Schumacher, Rainer Leupers
  • Publication number: 20170267313
    Abstract: A method as well as a device are described for use in a two-wheeler, in particular in an at least partially electrically drivable bicycle. In this context, the lift-off of at least one wheel is initially detected and a jump is inferred therefrom, possibly while utilizing further sensor signals. Then the risk is calculated that this jump may cause a rollover, e.g., over the handlebars or in the backward direction. In the event that this is the case, the at least one lifting-off wheel is acted upon in such a way that a counter torque is generated that counteracts the rotary motion leading to the rollover.
    Type: Application
    Filed: June 23, 2015
    Publication date: September 21, 2017
    Applicant: Robert Bosch GmbH
    Inventors: Christoph Schumacher, Johannes Alex Gerstenkorn Lavall
  • Publication number: 20170049738
    Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Inventors: Christoph SCHUMACHER, Thomas Holbro
  • Patent number: D851039
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 11, 2019
    Assignee: Robert Bosch GmbH
    Inventor: Christoph Schumacher
  • Patent number: D882513
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 28, 2020
    Assignee: Robert Bosch GmbH
    Inventor: Christoph Schumacher
  • Patent number: D882514
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 28, 2020
    Assignee: Robert Bosch GmbH
    Inventor: Christoph Schumacher
  • Patent number: D882515
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 28, 2020
    Assignee: Robert Bosch GmbH
    Inventor: Christoph Schumacher